KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET

Their core work

Frankfurt University Hospital (Universitätsklinikum Frankfurt) is a major German academic medical center that combines clinical care with biomedical research. Within H2020, they contribute clinical expertise and patient data to European rare disease networks and cancer research consortia. Their work spans rare disease diagnostics, gallbladder cancer biomarker research, and coordination of European research networks linking clinical practice with translational science.

What they specialise in

How they've shifted over time

Their H2020 involvement began in 2019 with a focus on rare diseases, FAIR data sharing, omics, and public-private partnerships through the EJP RD programme. By 2021, their portfolio expanded to include cancer-specific precision medicine (gallbladder cancer biomarkers, early detection) and broader European research network coordination via ERICA. The shift suggests a move from foundational rare disease data infrastructure toward more targeted clinical applications and international network building.

They are expanding from rare disease data sharing into precision medicine applications and intercontinental research partnerships, suggesting growing appetite for clinically translatable, globally connected projects.

How they like to work

Frankfurt University Hospital operates exclusively as a participant or third party — they have not coordinated any H2020 projects. They work in very large consortia (166 unique partners across 39 countries), which is typical of European Joint Programme-style projects. This suggests they contribute specialized clinical or data assets to large collaborative frameworks rather than driving project design themselves.

Despite only 3 projects, they are connected to 166 unique partners across 39 countries, a reflection of the very large rare disease consortia they participate in. Their network spans well beyond Europe into Latin America through the EULAT cancer project.

What sets them apart

Their dual focus on rare diseases and gallbladder cancer gives them an unusual combination of expertise in low-prevalence conditions where clinical data is scarce and international collaboration is essential. The European-Latin American link through EULAT is distinctive — few German university hospitals have active research ties to Andean countries. For consortium builders, they offer access to clinical data from a major German academic hospital embedded in wide international networks.

Highlights from their portfolio

• EJP RD
  Massive European Joint Programme on Rare Diseases — one of H2020's flagship rare disease initiatives connecting hundreds of partners across Europe.
• EULAT Eradicate GBC
  Unusual intercontinental scope linking European and Latin American cohorts for gallbladder cancer eradication, running through 2026.